Co-Authors
This is a "connection" page, showing publications co-authored by Christopher Goetz and Sue Leurgans.
Connection Strength
4.048
-
Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
Score: 0.324
-
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
Score: 0.316
-
Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
Score: 0.278
-
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
Score: 0.271
-
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
Score: 0.252
-
The role of the serotonin system in animal models of myoclonus. Adv Neurol. 2002; 89:244-8.
Score: 0.204
-
Posthypoxic myoclonus in the rat: natural history, stability, and serotonergic influences. Mov Disord. 2000; 15 Suppl 1:39-46.
Score: 0.178
-
Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale. Mov Disord. 1999 May; 14(3):502-6.
Score: 0.170
-
Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. Mov Disord Clin Pract. 2017 May-Jun; 4(3):412-415.
Score: 0.143
-
Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
Score: 0.097
-
Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord. 2009 May 15; 24(7):1070-3.
Score: 0.085
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
Score: 0.082
-
Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
Score: 0.081
-
Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
Score: 0.080
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
Score: 0.072
-
Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
Score: 0.070
-
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
Score: 0.069
-
Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
Score: 0.068
-
Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
Score: 0.067
-
Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
Score: 0.067
-
Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
Score: 0.063
-
Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology. 2003 Oct 14; 61(7):936-40.
Score: 0.058
-
Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
Score: 0.058
-
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
Score: 0.056
-
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
Score: 0.056
-
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
Score: 0.053
-
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
Score: 0.052
-
Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
Score: 0.052
-
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
Score: 0.051
-
Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
Score: 0.050
-
Home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome. Mov Disord. 2001 Jul; 16(4):693-7.
Score: 0.049
-
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
Score: 0.048
-
Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
Score: 0.047
-
Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000 Oct; 57(10):1461-3.
Score: 0.047
-
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
Score: 0.047
-
Objective changes in motor function during placebo treatment in PD. Neurology. 2000 Feb 08; 54(3):710-4.
Score: 0.045
-
Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
Score: 0.042
-
The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord. 1998 May; 13(3):490-6.
Score: 0.040
-
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
Score: 0.028
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Score: 0.021
-
Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
Score: 0.017
-
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
Score: 0.015
-
Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519.
Score: 0.013
-
Estrogen supplementation in the posthypoxic myoclonus rat model. Clin Neuropharmacol. 2001 Jan-Feb; 24(1):58-61.
Score: 0.012
-
Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
Score: 0.011
-
"On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
Score: 0.011
-
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
Score: 0.011
-
Animal model of posthypoxic myoclonus: effects of serotonergic antagonists. Neurology. 1999 Jan 01; 52(1):16-21.
Score: 0.010
-
Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
Score: 0.010